medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-27-8-17medalphabet-4053Research ArticleСтатьиАнемия в онкологической практике. Эральфон – оптимальная возможность персонификации лекарственной терапииAnemia in oncological practice. Eralfon – the optimal opportunity for personalization of drug therapyhttps://orcid.org/0000-0003-2981-7666БагроваС. Г.BagrovaS. G.

Багрова Светлана Геннадьевна, к.м.н., старший научный сотрудник отделения противоопухолевой лекарственной терапии № 1

Москва

Bagrova Svetlana G., PhD Med, senior researcher at Dept of Antitumor Drug Therapy No. 11

Moscow

s.bagrova@mail.ruhttps://orcid.org/0000-0001-7728-9533АртамоноваЕ. В.ArtamonovaE. V.

Артамонова Елена Владимировна, д.м.н., проф. кафедры онкологии и лучевой терапии; зав. кафедрой онкологии и торакальной хирургии; зав.отделением противоопухолевой лекарственной терапии № 1

Москва

Artamonova Elena V., DM Sci (habil.), professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery; head of Dept of Antitumor Drug Therapy No. 1

Moscow

ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Investigation Centre of OncologyRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России; ГБУЗ Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»; ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University; M. F. Vladimirsky Moscow Regional Research Clinical Institute; N.N. Blokhin National Medical Investigation Centre of OncologyRussian Federation202415122024027Диагностика и онкотерапия (3)817Copyright © Багрова С.Г., Артамонова Е.В., 20242024Багрова С.Г., Артамонова Е.В.Bagrova S.G., Artamonova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4053

Анемия оказывает заметное негативное влияние на качество жизни онкологических больных и определяет прогноз заболевания. Необходимость лечения анемии определяется ее отрицательным влиянием на продолжительность жизни, поскольку гипоксия, вызванная анемией, может ассоциироваться с резистентностью к химиотерапии, лучевой терапии, вызывает стимуляцию генетических мутаций и неоангиогенеза в опухоли, что затрудняет контроль над ней. Методы коррекции анемии определяются клинической картиной и проводимым противоопухолевым лечением. Применение гемотрансфузий ограничено и сопряжено с рядом рисков. Эритропоэз-стимулирующие препараты позволяют снизить потребность в гемотрансфузиях. В статье описаны механизмы действия, показания и побочные эффекты препаратов рекомбинантного эритропоэтина (рЭПО). Представлен анализ эффективности препаратов рЭПО при лечении анемии в онкологии на основании исторического опыта клинических исследований. Приведены рекомендации ведущих сообществ по применению препаратов рЭПО у различных категорий больных, отражен российский опыт применения эпоэтина альфа у пациентов, получающих химиотерапию. Использование эритропоэтинов четко всоответствии с показаниями позволяет значительно улучшить результаты лечения онкологических больных.

Anemia has a noticeable negative impact on the quality of life of cancer patients and determines the prognosis of the disease. The need to treat anemia is determined by its negative impact on life expectancy, since hypoxia caused by anemia can be associated with resistance to chemotherapy, radiation therapy, causes stimulation of genetic mutations and neoangiogenesis in the tumor, which makes it difficult to control it. The methods of correction of anemia are determined by the clinical picture and the antitumor treatment being carried out. The use of blood transfusions is limited and involves a number of risks. Erythropoiesis-stimulating drugs can reduce the need for blood transfusions. The article describes the mechanisms of action, indications and side effects of recombinant erythropoietin (rEPO) drugs. The analysis of the effectiveness of rEPO drugs in the treatment of anemia in oncology based on the historical experience of clinical trials is presented. The recommendations of the leading communities on the use of rEPO drugs in various categories of patients are presented, and the Russian experience of using epoetin alpha in patients receiving chemotherapy is reflected. The use of erythropoietins clearly in accordance with the indications can significantly improve the results of treatment of cancer patients.

анемияэритропоэтингемоглобинэпоэтин альфаэральфонхимиотерапиявыживаемостькачество жизнитромбоэмболические осложненияanemiaerythropoietinhemoglobinepoetin-alphaeralfonchemotherapysurvivalquality of lifethromboembolic complicationsReferencesБессмельцев С. С. Анемия при гематологических и солидных опухолях: патогенез, клинические проявления, методы коррекции. Bестник гематологии. 2024; XX (1): 4–33.Bessmeltsev S.S. Anemia in hematological and solid tumors: pathogenesis, clinical manifestations, correction methods. Bulletin of hematology. 2024; XX (1): 4–33. (In Russ.).Radziwon P., Krzakowski M., Wojtukiewicz M. Anemia in cancer patients – Expert Group recommendations. Revision 2020/ Published 2020. DOI: 10.5603/OCP.2020.0020 Medicine Oncology in Clinical Practice.Radziwon P., Krzakowski M., Wojtukiewicz M. Anemia in cancer patients – Expert Group recommendations. Revision 2020/ Published 2020. DOI: 10.5603/OCP.2020.0020 Medicine Oncology in Clinical Practice.Ludwig H., Van Belle S., Barrett-Lee P. et al. The European cancer anaemia survey: A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer. 2004; 40 (15): 2293–2306.Ludwig H., Van Belle S., Barrett-Lee P. et al. The European cancer anaemia survey: A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer. 2004; 40 (15): 2293–2306.Borbenyi Z. Etiology and treatment of malignancy-assotiated anaemia. Magy Onkol. 2001; 45: 437–441.Borbenyi Z. Etiology and treatment of malignancy-assotiated anaemia. Magy Onkol. 2001; 45: 437–441.Романенко Н.А., Бессмельцев С.С., Алборов А.Э. и др. Аспекты патогенеза анемии у пациентов онкологического профиля. Казанский медицинский журнал. 2019; 100 (6): 950–957. (In Russ.).Romanenko N.A., Bessmeltsev S. S., Alborov A. E. et al. Aspects of the pathogenesis of anemia in oncology patients. Kazan Medical Journal.2019; 100 (6): 950–957. (In Russ.).Mercadante S., Gebbia V., Marrazzo A. et al. Anemia in cancer: patophysiology and treatment. Cancer Treat. Rev. 2000; 26: 303–311.Mercadante S., Gebbia V., Marrazzo A. et al. Anemia in cancer: patophysiology and treatment. Cancer Treat. Rev. 2000; 26: 303–311.Cella D. The Functional Assessment of Cancer Therapy- Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997; 34 (3, Suppl. 2): 13–19.Cella D. The Functional Assessment of Cancer Therapy- Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997; 34 (3, Suppl. 2): 13–19.Elliot S., Sinclair A.M. The effect of erythropoietin on normal and neoplastic cellc. Biologics: Targets and Therapy. 2012; 6: 163–189.Elliot S., Sinclair A.M. The effect of erythropoietin on normal and neoplastic cellc. Biologics: Targets and Therapy. 2012; 6: 163–189.Wang W., Mao-Hong Zhang, Yuan Yu, Cong-gao Xu Influence of Tumor Necrosis Factor-Alpha and Interferon-Gamma on Erythropoietin Production and Erythropoiesis in Cancer Patients with Anemia. 2007; 28 (10): 681–684.Wang W., Mao-Hong Zhang, Yuan Yu, Cong-gao Xu Influence of Tumor Necrosis Factor-Alpha and Interferon-Gamma on Erythropoietin Production and Erythropoiesis in Cancer Patients with Anemia. 2007; 28 (10): 681–684.Smith T.G., Robbins P.A., Ratcliffe P.J. The human side of hypoxia-inducible factor. Br.J. Haematol. 2008; 141 (3): 325–334.Smith T.G., Robbins P.A., Ratcliffe P.J. The human side of hypoxia-inducible factor. Br.J. Haematol. 2008; 141 (3): 325–334.Бессмельцев С.С. Современные подходы к лечению анемии у больных со злокачественными новообразованиями. Онкология. 2008; 10 (2): 275–283.Бессмельцев С.С. Современные подходы к лечению анемии у больных со злокачественными новообразованиями. Онкология. 2008; 10 (2): 275–283.Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Rev. Churchill Livingstone. 2015; 29 (5): 291–299.Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Rev. Churchill Livingstone. 2015; 29 (5): 291–299.Клинические рекомендации по онкологии: Анемия при злокачественных новообразованиях. https://oncology.ru/specialist/treatment/references/actual/624.pdfClinical guidelines for oncology: Anemia in malignant neoplasms. (In Russ.). https://oncology.ru/specialist/treatment/references/actual/624.pdfОрлова Р.В., Гладков О.А., Кутукова С.И., Копп М.В., Королева И.А., Ларионова В.Б. и соавт. Практические рекомендации RUSSCO, часть 2 Злокачественные опухоли. 2023. Т. 13, #3s2. С. 22–28.Orlova R.V., Gladkov O.A., Kutukova S.I., Kopp M.V., Koroleva I.A., Larionova V.B. et al. RUSSCO Practical Recommendations, Part 2 Malignant Tumors. 2023; 13 (#3s2): 22–28. (In Russ.).Bohlius J., Bohlke K., Castelli R., Djulbegovic B., Lustberg M.B., Martino M. et al. Management of cancer-associated anemia with erythropoiesisstimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019; 3 (8): 1197–1210. https://doi.org/10.1182/bloodadvances.2018030387Bohlius J., Bohlke K., Castelli R., Djulbegovic B., Lustberg M.B., Martino M. et al. Management of cancer-associated anemia with erythropoiesisstimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019; 3 (8): 1197–1210. https://doi.org/10.1182/bloodadvances.2018030387Aapro M., Beguin Y. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†/supportive and palliative care. Vol. 29, supplement 4, iv96-iv110, Oct 2018.Aapro M., Beguin Y. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†/supportive and palliative care. Vol. 29, supplement 4, iv96-iv110, Oct 2018.Aapro M. Emerging topics in anaemia and cancer. Supportive and palliative care| volume 23, supplement 10, x289–x293, Sept 2012: //www.annalsofoncology.org/article/S0923–7534(19)Aapro M. Emerging topics in anaemia and cancer. Supportive and palliative care| volume 23, supplement 10, x289–x293, Sept 2012: //www.annalsofoncology.org/article/S0923–7534(19)Álvarez Y.E., de las Peñas Bataller R., Altozano J.P. et al. SEOM clinical guidelines for anaemia treatment in cancer patients. Clin. Transl. Oncol. 2021; 23 (5): 931–939.Álvarez Y.E., de las Peñas Bataller R., Altozano J.P. et al. SEOM clinical guidelines for anaemia treatment in cancer patients. Clin. Transl. Oncol. 2021; 23 (5): 931–939.Pernice M., Manci N. et al. Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Gynecologic tumors. Vol. 18, issue 4, p. 722–729, Apr 2007.Pernice M., Manci N. et al. Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Gynecologic tumors. Vol. 18, issue 4, p. 722–729, Apr 2007.Hidekazu Tanaka et al. Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Cancer Management and Research. 2021; 13: 7447–7453.Hidekazu Tanaka et al. Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Cancer Management and Research. 2021; 13: 7447–7453.Jennyfer E. Garcia-Arispe. Аnemia and cancer survival, a peruvian 5-year follow-up study. Rev. Fac. Med. Hum. Enero. 2021; 21 (1): 90–100. DOI: 10.25176/RFMH.v21i1.3460Jennyfer E. Garcia-Arispe. Аnemia and cancer survival, a peruvian 5-year follow-up study. Rev. Fac. Med. Hum. Enero. 2021; 21 (1): 90–100. DOI: 10.25176/RFMH.v21i1.3460Wenjie Zhu, Binghe Xu. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS One. 2015 Aug 20; 10 (8): e0136268.Wenjie Zhu, Binghe Xu. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS One. 2015 Aug 20; 10 (8): e0136268.Tee M., Shubert C. Preoperative anemia is associated with increased use of hospital resources in patients undergoing elective hepatectomy. Published in Surgery 1 October 2015. Medicine.Tee M., Shubert C. Preoperative anemia is associated with increased use of hospital resources in patients undergoing elective hepatectomy. Published in Surgery 1 October 2015. Medicine.J. Jo, S. The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Int Urol. Nephrol. 2016 Apr; 48 (4): 489–94.J. Jo, S. The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Int Urol. Nephrol. 2016 Apr; 48 (4): 489–94.Berezin P.G., Milovanov V.V., Ivannikov A.A. The role of erythropoietin in treatment of anemia in cancer patients. Research and Practical Medicine Journal. 2017; 4 (2): 37–42.Berezin P.G., Milovanov V.V., Ivannikov A.A. The role of erythropoietin in treatment of anemia in cancer patients. Research and Practical Medicine Journal. 2017; 4 (2): 37–42.Management of Cancer-Associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ ASH Clinical Practice Guideline Update / Julia Bohlius. Journal of Clinical Oncology. 2019 April 10; 37 (15).Management of Cancer-Associated Anemia with Erythropoiesis-Stimulating Agents: ASCO/ ASH Clinical Practice Guideline Update / Julia Bohlius. Journal of Clinical Oncology. 2019 April 10; 37 (15).Glaspy J., Degos L., Dicato M., Demetri G.D. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and non-platinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7 (2): 126–35.Glaspy J., Degos L., Dicato M., Demetri G.D. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and non-platinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7 (2): 126–35.Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002; 87: 1209–1221.Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002; 87: 1209–1221.Tonelli M., Hemmelgarn B., Reiman T. et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. CMAJ. 2009; 180: E62–E71.Tonelli M., Hemmelgarn B., Reiman T. et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. CMAJ. 2009; 180: E62–E71.David A Gewirtz, Xu Di, Teneille D Walker, Stephen T Sawyer Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin. Cancer Res. 2006; 12 (7 I): 2232–2238. DOI: 10.1158/1078-0432David A Gewirtz, Xu Di, Teneille D Walker, Stephen T Sawyer Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin. Cancer Res. 2006; 12 (7 I): 2232–2238. DOI: 10.1158/1078-0432Parsa C.J. Matsumoto A., Kim J. et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003; 112 (7): 999–1007.Parsa C.J. Matsumoto A., Kim J. et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003; 112 (7): 999–1007.Tonia T., Mettler A., Robert N. et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12: CD003407.Tonia T., Mettler A., Robert N. et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12: CD003407.Меркулов В.А., Солдатов А.А. и др. Препараты рекомбинантных эритропоэтинов и их характеристика. Merkulov V.A., Soldatov A.A. et al. Recombinant erythropoietin preparations and their characteristics. (In Russ.). https://cyberleninka.ru/article/n/preparaty-rekombinantnyh-eritropoetinov-i-ih-harakteristika/viewerMerkulov V.A., Soldatov A.A. et al. Recombinant erythropoietin preparations and their characteristics. (In Russ.). https://cyberleninka.ru/article/n/preparaty-rekombinantnyh-eritropoetinov-i-ih-harakteristika/viewerBohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532–1542.Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532–1542.Boulaamane L., Goncalves A. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. Supportive Care in Cancer / Vol. 21, p. 2359–2369 (2013).Boulaamane L., Goncalves A. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. Supportive Care in Cancer / Vol. 21, p. 2359–2369 (2013).Smith R.E. Jr., Aapro M.S., Ludwig H. et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 2008; 26 (7): 1040–1050.Smith R.E. Jr., Aapro M.S., Ludwig H. et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 2008; 26 (7): 1040–1050.Isabelle Ray-Coquard1, Jean-François Morère, Florian Scotté. et al. Management of Anemia in Advanced Breast and Lung Cancer Patients in Daily Practice: Results of a French Survey. Original Research/Published: 07 February 2012/Vol. 29, p. 124–133 (2012).Isabelle Ray-Coquard1, Jean-François Morère, Florian Scotté. et al. Management of Anemia in Advanced Breast and Lung Cancer Patients in Daily Practice: Results of a French Survey. Original Research/Published: 07 February 2012/Vol. 29, p. 124–133 (2012).Leyland-jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 2005; 23: 5960–5972.Leyland-jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 2005; 23: 5960–5972.Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Michael Henke 1, Roland Laszig, Lancet. 2003 Oct 18; 362 (9392): 1255–60.Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Michael Henke 1, Roland Laszig, Lancet. 2003 Oct 18; 362 (9392): 1255–60.Eric Abhold, Elham Rahimy, Jessica Wang-Rodriguez et al. Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro, BMC Research Notes. Volume 4, Article number: 553 (2011).Eric Abhold, Elham Rahimy, Jessica Wang-Rodriguez et al. Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro, BMC Research Notes. Volume 4, Article number: 553 (2011).James R Wright et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J. Clin. Oncol. 2007 Mar 20; 25 (9): 1027–32. DOI: 10.1200/JCO.2006.07.1514. Epub 2007 Feb 20.James R Wright et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J. Clin. Oncol. 2007 Mar 20; 25 (9): 1027–32. DOI: 10.1200/JCO.2006.07.1514. Epub 2007 Feb 20.Michael Hedenus. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br.J. Haematol. 2003 Aug; 122 (3): 394–403.Michael Hedenus. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br.J. Haematol. 2003 Aug; 122 (3): 394–403.Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br.J. Cancer. 2010; 102: 301–315.Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br.J. Cancer. 2010; 102: 301–315.Moebus V., Jackisch C., Lueck H. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J. Clin. Oncol 2010; 28: 2874–2880.Moebus V., Jackisch C., Lueck H. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J. Clin. Oncol 2010; 28: 2874–2880.Hershman DL, Buono DL, Malin J. et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J. Natl. Cancer Inst. 2009; 101: 1633–1641.Hershman DL, Buono DL, Malin J. et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J. Natl. Cancer Inst. 2009; 101: 1633–1641.Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76 (3): 478–85. DOI: 10.1016/j.lungcan.2011.12.015. Epub 2012 Jan 25. PMID: 22277104.Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76 (3): 478–85. DOI: 10.1016/j.lungcan.2011.12.015. Epub 2012 Jan 25. PMID: 22277104.NCCN Guidelines Version 3.2024 Hematopoietic Growth Factors. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdfNCCN Guidelines Version 3.2024 Hematopoietic Growth Factors. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdfBennett CL, Silver SM, Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914–924.Bennett CL, Silver SM, Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914–924.Ping Zhan, Qin Wang et al. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials Meta-Analysis Chinese Clinical Oncology. 2012 Dec 01; 1 (2).Ping Zhan, Qin Wang et al. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials Meta-Analysis Chinese Clinical Oncology. 2012 Dec 01; 1 (2).Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116: 4045–4059.Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116: 4045–4059.Эральфон, раствор для внутривенного и подкожного введения. РУ ЛП008414 от 03.08.2022, РУ ЛСР008793/10 от 26.08.2010, РУ ЛСР000971/10 от 15.02.2010, РУ ЛСР006663/08 от 15.08.2008.Eralfon, solution for intravenous and subcutaneous administration, RU LP008414 dated 03.08.2022, RU LSR008793/10 dated 26.08.2010, RU LSR000971/10 dated 15.02.2010, RU LSR006663/08 dated 15.08.2008. (In Russ.).Владимирова Л.Ю., Абрамова Н.А., Льянова А.А. и др. Эпоэтин альфа в лечении анемии у пациентов со злокачественными солидными опухолями в процессе проведения противоопухолевой лекарственной терапии. Медицинский совет. 2022; 16 (9): 117–125.Vladimirova L. Yu., Abramova N.A., Lyanova A.A. et al. Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy. Medical Council. 2022; 16 (9): 117–125. (In Russ.).Большакова С. А., Бычков Ю.М., Казарова М. В. Собственный опыт использования эпоэтина-a (Эральфон®) в лечении анемии, индуцированной воздействием цитостатиков. Современная Онкология. 2017; 19 (1): 80–84.Bolshakova S.A., Bychkov Yu.M., Kazarova M.V. Personal experience of using epoetin-a (Eralfon®) in the treatment of anemia induced by cytostatics. Modern Oncology. 2017; 19 (1): 80–84. (In Russ.).Крысанов И.С., Макарова Е.В., Ермакова В.Ю. Сравнительный фармакоэкономический анализ применения эритропоэз-стимулирующих препаратов для лечения анемии у онкологических пациентов. Медицинский совет. 2021; (20): 174–182.Krysanov I.S., Makarova E.V., Ermakova V. Yu. Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients. Medical Council. 2021; (20): 174–182. (In Russ.).Ларионова В.Б., Крысанов И.С., Снеговой А.В. и др. Рациональная тактика поддерживающей терапии анемии, индуцированной химиотерапией: фармакоэкономический анализ применения эритропоэз-стимулирующих препаратов у пациентов с онкологическими заболеваниями в условиях здравоохранения Российской Федерации. Онкогематология. 2018; 13 (2): 48–61.Larionova V.B., Krysanov I.S., Snegovoy A.V. et al. Rational tactics of maintenance therapy of anemia induced by chemotherapy: pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs in patients with cancer in the healthcare conditions of the Russian Federation. Oncohematology. 2018; 13 (2): 48–61. (In Russ.).Pashos C.L., Larholt K., Fraser K.A. et al. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Support Care Cancer. 2012; 20 (1): 159–65. DOI: 10.1007/s0052001010837. PMID: 21359879.Pashos C.L., Larholt K., Fraser K.A. et al. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Support Care Cancer. 2012; 20 (1): 159–65. DOI: 10.1007/s0052001010837. PMID: 21359879.

The authors declare that there are no conflicts of interest present.